Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncorena
Mandate

Vinge advises Oncorena

January 13, 2022

Vinge advises Oncorena Holding AB in connection with an investment of initially SEK 66 million from Linc, HealthCap and Fåhraeus Startup and Growth.

The investment will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients with advanced kidney cancer. In the event that the initial part of the clinical study provides positive results, the investors intend to finance the second part of the study with an additional SEK 94 million.

 

The Vinge team includes Christian Lindhé, Martin Svanberg and Sofie Nordgren.

Related

Vinge is advising on the establishment of Ballista Capital

 Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025

Vinge advises The Qt Company Ltd on its public offer for I.A.R. Systems Group AB (publ)

The Qt Company Ltd (“The Qt Company”), a wholly owned subsidiary of Qt Group Plc, has announced a public tender offer to the shareholders of I.A.R. Systems Group AB (publ) (“IAR”) to tender all class B shares in IAR to The Qt Company at a price of SEK 180 in cash per share
July 04, 2025

Vinge has advised Consolid on the establishment of Consolid Equity III

 The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.
July 02, 2025